No Data
No Data
Institutional Investors Have a Lot Riding on Relmada Therapeutics, Inc. (NASDAQ:RLMD) With 48% Ownership
Express News | CORRECTION: (Reported June 18, 2024) Relmada Therapeutics Announced Publication Of Results From The Phase 3 Reliance I Study of REL-1017 In The Journal Of Clinical Psychiatry
Earlier, Relmada Therapeutics Announced Publication Of Results From The Phase 3 Reliance I Study of REL-1017 In The Journal Of Clinical Psychiatry
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Relmada Therapeutics Price Target Cut to $2.00/Share From $3.00 by Goldman Sachs
No Data